MedTrace Logo

RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial

NCT05049668 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 197

Last updated 2021-09-27

No results posted yet for this study

Summary

After exiting the RACE trial (NCT02099747) patients will be invited to participate in this long term follow-up study

Conditions

  • Severe Aplastic Anemia

Interventions

DRUG

ATGAM plus CsA with or without Eltrombopag

Standard treatment with or without Eltrombopag

Sponsors & Collaborators

  • European Society for Blood and Marrow Transplantation

    lead NETWORK

Principal Investigators

  • Regis Peffault de Latour, Prof, MD · Hospital St. Louis, Paris, France

  • Antonio M Risitano, MD, PhD · Hospital Avellino, Napels, Italy

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2033-12-31
Completion
2034-12-31
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05049668 on ClinicalTrials.gov